Pharnext S.C.A. (EPA:ALPHA)
France · Delayed Price · Currency is EUR 0.0002
0.00 (0.00%)
Inactive · Last trade price on Feb 14, 2025
Pharnext S.C.A. Company Description
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases.
Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases.
The company was incorporated in 2007 and is headquartered in Suresnes, France.
Pharnext S.C.A.
| Country | France |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Hugo Brugiere |
Contact Details
Address: 14 rue de la REpublique Suresnes, 92150 France | |
| Website | pharnext.com |
Stock Details
| Ticker Symbol | ALPHA |
| Exchange | Euronext Paris |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR001400BV89 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hugo Brugiere M.Sc. | Chief Executive Officer and Chairman |
| Daniel E. Cohen M.D., Ph.D. | Director |
| Ilya Chumakov D-Sc, Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Director |
| Vincent Serra Ph.D. | Chief Operating Officer and Chief Scientific Officer |
| Raj Thota M.Sc. | Chief Manufacturing Officer and Head of CMC |
| Gilbert Wagener M.D., Ph.D. | Chief Medical Officer |